Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.

For instance, within the CPS ≥ 20 population, pembrolizumab monotherapy compared to EXTREME resulted in a net gain of 4.2 mo in terms of OS (14.9 mo vs 10.7 mo) with a highly significant 39% reduction in risk of death (HR = 0.61, P = 0.0007).

also in 132,142 other papers